

## Appendix 3B

### New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Class Limited

ABN

70 116 802 058

We (the entity) give ASX the following information.

#### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |  |
|---|---|--|
| 1 | +Class of +securities issued or to be issued  | Unlisted Performance Rights (Tranche 4)<br>Unlisted Deferred Rights (FY19 STI) |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 498,550 Unlisted Performance Rights<br>224,835 Unlisted Deferred Rights        |

## Appendix 3B

### New issue announcement

---

<p>3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)</p>	<p>Performance Rights are issued under the terms of the Class Limited Performance Rights and Deferred Rights Plan as approved by shareholders on 15 October 2018 (<b>Rights Plan</b>).</p> <p>The vesting of Performance Rights is subject to certain performance criteria measured over the three year performance period ending 30 June 2022 in accordance with the terms of the Rights Plan.</p> <p>Deferred Rights issued under the terms of the Rights Plan. The Deferred Rights will vest in equal instalments on 1 September 2020 and 1 September 2021 but are not subject to any performance criteria.</p>
<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"><li>• the date from which they do</li><li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li><li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li></ul>	<p>Prior to vesting, the Performance Rights and Deferred Rights do not carry a right to vote or receive dividends or distributions.</p> <p>All shares allotted on vesting of the Performance Rights or Deferred Rights will rank pari passu in all respects with existing Fully Paid Ordinary Shares on issue and, in particular, entitle the holders to participate fully in:</p> <ul style="list-style-type: none"><li>• dividends declared by the Company after the date of allotment; and</li><li>• all issues of securities made or offered pro rata to holders of Shares.</li></ul>
<p>5 Issue price or consideration</p>	<p>Consideration for the grant of Performance Rights and Deferred Rights is Nil (the exercise price per Performance Right and per Deferred Right is Nil)</p>

---

+ See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<p>The Performance Rights are granted to Eligible Employees in respect of the FY20 LTI award made under the terms of the Rights Plan.</p> <p>The Deferred Rights are granted to Eligible Employees in respect of the FY19 STI award made under the terms of the Rights Plan.</p>
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of +securities issued without security holder approval under rule 7.1	N/A
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of +securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A					
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A					
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	1 November 2019					
8	Number and +class of all +securities quoted on ASX ( <i>including</i> the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="711 880 995 913">Number</th> <th data-bbox="995 880 1294 913">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="711 913 995 1128">117,662,056</td> <td data-bbox="995 913 1294 1128">Fully Paid Ordinary Shares</td> </tr> </tbody> </table>	Number	+Class	117,662,056	Fully Paid Ordinary Shares	
Number	+Class						
117,662,056	Fully Paid Ordinary Shares						

---

+ See chapter 19 for defined terms.

	Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	
	793,506	“Series 2” Options – unlisted options which vested on 30 September 2018, have an exercise price of \$1.33 and expire on 30 September 2020
	708,202	“Series 3” Options – unlisted options which have vested, have an exercise price of \$3.81 and expire on 30 June 2021
	515,997	“Series 4” Options – unlisted options which have vested, have an exercise price of \$3.99 and expire on 15 March 2022
	348,671	“Series 4” Options – unlisted options which vest in three equal instalments on 1 July 2020, have an exercise price of \$3.99 and expire on 15 March 2022
	168,664	“Tranche 1” Performance Rights – unlisted performance rights which vest subject to certain performance criteria measured over the three year performance period ending 30 June 2021
	800,000	“Tranche 2” Performance Rights – unlisted performance rights which vest subject to certain performance criteria measured over the three year performance period ending 13 May 2022.
	697,023	“Tranche 4” Performance Rights – unlisted performance rights which vest subject to certain performance criteria measured over the three year performance period ending 30 June 2022.
	224,835	FY19 STI Deferred Rights – unlisted deferred rights which vest in equal instalments on 1 September 2020 and 1 September 2021.

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change
----	--	-----------

**Part 2 - Pro rata issue**

11	Is security holder approval required?	N/A
----	---------------------------------------	-----

12	Is the issue renounceable or non-renounceable?	N/A
----	--	-----

13	Ratio in which the +securities will be offered	N/A
----	--	-----

14	+Class of +securities to which the offer relates	N/A
----	--	-----

15	+Record date to determine entitlements	N/A
----	--	-----

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
----	--	-----

17	Policy for deciding entitlements in relation to fractions	N/A
----	---	-----

18	Names of countries in which the entity has security holders who will not be sent new offer documents  <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A
----	--	-----

19	Closing date for receipt of acceptances or renunciations	N/A
----	--	-----

20	Names of any underwriters	N/A
----	---------------------------	-----

21	Amount of any underwriting fee or commission	N/A
----	--	-----

22	Names of any brokers to the issue	N/A
----	-----------------------------------	-----

---

+ See chapter 19 for defined terms.

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	+Issue date	N/A

---

+ See chapter 19 for defined terms.

## Appendix 3B New issue announcement

---

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of +securities  
(tick one)

(a)  +Securities described in Part 1

(b)  All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

---

+ See chapter 19 for defined terms.

**Entities that have ticked box 34(b)**

38	Number of +securities for which +quotation is sought	N/A				
39	+Class of +securities for which quotation is sought	N/A				
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	N/A				
41	<p>Reason for request for quotation now</p> <p><small>Example: In the case of restricted securities, end of restriction period</small></p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>	N/A				
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; text-align: center;">Number</th> <th style="width: 50%; text-align: center;">+Class</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">N/A</td> <td style="padding: 5px;"></td> </tr> </tbody> </table>	Number	+Class	N/A	
Number	+Class					
N/A						

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: .....  
Company secretary

Date: 4 November 2019

Print name: Glenn Day

=====

---

+ See chapter 19 for defined terms.